Loading...
Loading...
MDMA-Assisted Therapy: FDA Breakthrough Therapy for extinguishing traumatic memories.
MDMA is not a classic psychedelic but an "empathogen" or "entactogen." It reduces fear response while enhancing feelings of trust and empathy—creating an ideal state for processing traumatic memories.
No longer met PTSD criteria
(vs. 32% placebo)
Significant symptom reduction
(≥10 point CAPS-5 drop)
8-hour dosing sessions
Spaced 4 weeks apart
Fear center quiets, allowing approach to traumatic memories without overwhelm.
Bonding hormones increase, enhancing therapeutic alliance and self-compassion.
Positive mood state enables compassionate self-reflection.
Rational brain can communicate effectively with emotional brain.
• Cardiovascular: Increases HR and BP. Strictly contraindicated in uncontrolled hypertension or heart disease.
• Serotonin Syndrome: Fatal risk with SSRIs/MAOIs. Mandatory washout period required.
• Neurotoxicity: Heavy recreational use damages serotonin axons. Clinical dosing appears safe, but cooling is recommended.
• The Comedown: "Blue Monday" dip in mood 2-3 days later. Mitigated with 5-HTP and integration.
Expected 2024-2025. Current access via Clinical Trials or Expanded Access only.